AAVB-039

BIOLOGICAL2 trials

Sponsors

Aavantgarde Bio S.r.l., AAVantgarde Bio Srl

Conditions

Stargardt DiseaseStargardt Disease (STGD1)

Phase 1

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

RecruitingNCT07161544

AAVantgarde Bio SrlStargardt Disease

Start: 2025-09-29End: 2032-07-01Target: 75Updated: 2026-07-30

An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease (STGD1) (CELESTE)

Not yet recruitingCTIS2025-522207-15-01

Aavantgarde Bio S.r.l.Stargardt Disease (STGD1)

Target: 3Updated: 2026-04-10